Hospital Nuclear Medicine Radiopharmaceuticals 
AuntMinnie
APRIL 15, 2024
Total nuclear medicine patient study volumes decreased by 5.7% decrease in hospital-based studies and a 2.5% decrease in total procedures each year, with hospital-based procedures declining by 5.5% and non-hospital procedures increasing by 1.2%. and non-hospital procedures increasing by 1.2%. Of these, 5.8
Imaging Technology
NOVEMBER 7, 2024
1, 2024 — The Centers for Medicare & Medicaid Services (CMS) have announced a significant adjustment to the Hospital Outpatient Prospective Payment System (HOPPS). We commend CMS for this significant move to improve access to life-saving nuclear medicine scans, ensuring that patients across the country can receive the best possible care.”
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuntMinnie
JULY 10, 2024
Centers for Medicare and Medicaid Services (CMS) proposed a new reimbursement plan July 10 for diagnostic PET scans that would provide separate payments for radiopharmaceuticals, as well as an extra payment for hospitals when they use domestically produced technetium-99m (Tc-99m).
AuntMinnie
MARCH 7, 2024
In terms of 2023 spending, the average radiopharmaceutical expenditure per fixed PET site is estimated to be $517,000. In 2023, 38% of PET systems were operated by the PET department, 28% by nuclear medicine, 24% by radiology/imaging, 5% by radiation oncology, and 2% by molecular imaging.
AuntMinnie
JULY 12, 2024
As nuclear medicine therapies gain stature compared to nuclear medicine in diagnostic imaging, hospital administrators may be eyeing the potential of adding theranostics services. A shortage of nuclear medicine technologists means a theranostics center may need to limit its patient volume.
AuntMinnie
JUNE 3, 2024
With therapeutic radiopharmaceuticals coming to market quickly and available to smaller institutions around the U.S., My vision of a theranostic center includes a flagship facility that has a PET/CT scanner, a SPECT/CT scanner, and then multiple rooms for infusions of radiopharmaceuticals," Siegel explained.
AuntMinnie
MAY 8, 2024
Theranostics treatments are used with increasing frequency now since the approvals and expansions of Lutathera (lutetium-177 [Lu-177]) DOTATATE, a radiopharmaceutical for neuroendrocrine tumors (NETs) and Pluvicto, Lu-177 PSMA-617, for prostate cancer. In addition, dose calculations estimated mean dose to the arm of approximately 3 Gy.
Expert insights. Personalized for you.
111 
Let's personalize your content